Congress Asset Management Co. Cuts Stock Holdings in Boston Scientific Corporation $BSX

Congress Asset Management Co. reduced its position in Boston Scientific Corporation (NYSE:BSX) by 1.0% in the second quarter, Holdings Channel.com reports. The fund owned 1,701,570 shares of the medical equipment provider’s stock after selling 17,258 shares during the period. Boston Scientific makes up about 1.3% of Congress Asset Management Co.’s investment portfolio, making the stock its 16th largest position. Congress Asset Management Co.’s holdings in Boston Scientific were worth $182,766,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in shares of Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares during the last quarter. Ameriflex Group Inc. purchased a new position in Boston Scientific in the 4th quarter worth about $31,000. PKO Investment Management Joint Stock Co purchased a new stake in shares of Boston Scientific during the 4th quarter valued at about $893,000. MassMutual Private Wealth & Trust FSB grew its stake in shares of Boston Scientific by 17.5% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 6,325 shares of the medical equipment provider’s stock worth $638,000 after acquiring an additional 940 shares during the period. Finally, Neville Rodie & Shaw Inc. purchased a new position in shares of Boston Scientific during the first quarter valued at approximately $2,341,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Down 0.0%

Shares of Boston Scientific stock opened at $98.03 on Friday. Boston Scientific Corporation has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The company has a market capitalization of $145.26 billion, a P/E ratio of 58.35, a P/E/G ratio of 2.36 and a beta of 0.65. The company has a fifty day moving average of $103.90 and a 200 day moving average of $102.06.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the business earned $0.62 earnings per share. The business’s revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the sale, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $18,397,457 over the last ninety days. 0.50% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Barclays lifted their target price on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. UBS Group lifted their price objective on Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Robert W. Baird upped their price objective on Boston Scientific from $117.00 to $123.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. BTIG Research reissued a “buy” rating and issued a $127.00 target price on shares of Boston Scientific in a research report on Tuesday. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Boston Scientific in a research note on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $118.17.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.